Moleculin Biotech, Inc. (NASDAQ:MBRX) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on March 09, 2026.
The Healthcare company's proxy statement provides information for shareholders ahead of the annual meeting, including board nominations, executive compensation, and proposals for shareholder vote.
Moleculin Biotech, Inc.'s stock currently trades at $1.96 with a market capitalization of $6.0M.
SEC filings provide mandatory disclosures that give investors access to the same material information available to institutional investors. Reviewing Moleculin Biotech, Inc.'s filings alongside price action and analyst commentary provides a more complete picture of the company's current situation.
All SEC filings for Moleculin Biotech, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.